Our technology

Our Technology

The future of medical diagnostics is Lab-on-a-chip, this technology offers a wide array of possible advantages over traditional benchtop operations for performing point of care clinical diagnostics in device avoiding the need to use laboratory facilities and complex scientific equipment. SENZORIN bio chip is a smart microprocessor designed purely for medical applications analysing multiple diseases all on single chip.

Importance of the Biochip

The biochip is the platform that makes quantum‑enhanced diagnostics practical: it integrates microfluidics, multiplexed sensing arrays, and on chip signal processing into a compact, manufacturable device. By bringing sample handling, reagent control, and readout onto a single chip, SENZORIN’s platform reduces sample loss, shortens assay workflows, and enables simultaneous measurement of many biomarkers from a tiny sample volume.
These on chip capabilities are essential for translating laboratory quantum sensors into routine clinical tools.

Our Technology

We fuse quantum sensing and processing with materials and design principles proven in space applications to achieve exceptional sensitivity, stability, and miniaturisation. The result is a world leading chip platform that detects biological signals at previously unreachable scales and delivers results in a fraction of the time of conventional methods.

The future of medical diagnostics is Lab-on-a-chip, this technology offers a wide array of possible advantages over traditional benchtop operations for performing point of care clinical diagnostics in device avoiding the need to use laboratory facilities and complex scientific equipment. SENZORIN bio chip is a smart microprocessor designed purely for medical applications analysing multiple diseases all on single chip.

Why Quantum Matters

Quantum technologies are important for developing next generation medical biochips because they offer far greater sensitivity and new ways to sense biological signals, enabling earlier and faster detection of cancer from tiny samples. By using quantum-based sensors and nanoscale probes integrated with microfluidic chips, these devices can pick up faint molecular or magnetic signatures that conventional sensors miss, reducing the need for large volumes or lengthy preparation.

Quantum approaches also improve specificity by resolving subtle molecular features, which helps distinguish true disease markers from background noise and lowers false positives. Combined with compact, chip scale architectures, these advances make rapid, label‑free assays and multiplexed testing feasible at the point of care, potentially moving screening out of centralized labs and into clinics or community settings. Translation to clinical use will require solving engineering, cost, and validation challenges, but the potential to detect cancer earlier and more reliably makes quantum-enabled biochips a promising direction.